X

Trial Profile

A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CUE-102 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Cue Biopharma

Most Recent Events

10 Jul 2024 Status changed from recruiting to active, no longer recruiting.
04 Jun 2024 Results (n=28, of the dose-finding portion (Part A) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2024 According to a Cue Biopharma media release, dose escalation part of the Phase 1 has been full enrolled and dose expansion part is ongoing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com